March 1, 2004 — From Italy, there’s news that a vaccine seems to slow — or indeed halt — the development of breast cancer in mice. It may lead to a unused breast cancer treatment and possibly a new preventive measure, researchers say.
It’s another “to begin with” in a worldwide exertion pointed at developing a breast cancer antibody. Past tests have found that a antibody can trigger the body to launch an all-out safe framework assault against cancer cells.
Be that as it may, it’s not been clear whether this actually stops tumor development, composes lead researcher Elena Quaglino, MD, a biologist with the College of Turin in Orbassano, Italy.
Quaglino’s ponder shows up in this week’s issue of the Diary of Clinical InvestigationJournal of Clinical Examination.
Her think about involved mice extraordinarily bred to have parts of the HER-2/neu breast cancer gene. Ten weeks after they were born, the mice showed far reaching signs of cancerous breast tissue that ordinarily progress to fast-growing, invasive, metastatic tumors.
At that point, half the mice were given a vaccination to boost an immune system reaction against a protein — called rp 185neu, a frame of HER-2/neu — found in abundance on precancerous and early breast cancer cells in these mice. A week later, those same mice got a booster shot too composed of cells built to release interferon-gamma, a chemical that revs up the resistant system.
The advancement of tumors was altogether deferred and kept 48% of the immunized mice tumor-free until the test ended at week 32.
Inoculation against this protein for early breast cancer may be an successful treatment procedure in people, agreeing to the researchers. Be that as it may, it’s not however clear how well the inoculation would work against human breast cancer.
This exploratory breast cancer treatment may be best saved for women who cannot have surgery since of other irrelevant conditions, she notes. In expansion, it may be useful to assist anticipate breast cancer repeat in women after surgery.
SOURCE: Quaglino, E. The Journal of Clinical Investigation, Walk 2004; vol 113: pp 709-717.
Recente reacties